QUANTITY LIMIT CRITERIA

DRUG CLASS SHORT ACTING BETA2-ADRENERGIC AGONIST ORAL INHALATION

BRAND NAME (generic)

(albuterol inhalation solution)

PROAIR DIGIHALER

(albuterol)

PROAIR HFA (albuterol)

PROAIR RESPICLICK

(albuterol)

PROVENTIL HFA

(albuterol)

VENTOLIN HFA

(albuterol)

XOPENEX SOLUTION

(levalbuterol)

XOPENEX CONCENTRATE

(levalbuterol)

XOPENEX HFA (levalbuterol)

Status: CVS Caremark Criteria

Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Albuterol Inhalation Solution 0.63mg/3mL (0.021%) and 1.25mg/3mL (0.042%)

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).

Albuterol Inhalation Solution 0.083% (2.5mg/3mL)

Albuterol sulfate inhalation solution 0.083% is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

Albuterol Inhalation Solution 0.5% (2.5mg / 0.5mL)

0.5mL Vial

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 12 year of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

20mL Bottle

Beta Agonists-Short Acting Oral Inhalation Limit Policy 1086-H 11-2020.docx

©2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

ProAir Digihaler

Bronchospasm

ProAir Digihaler inhalation powder is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

ProAir Digihaler is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

ProAir HFA

Bronchospasm

ProAir HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Proair HFA Inhalation Aerosol is indicated for the prevention of exercise induced bronchospasm in patients 4 years of age and older.

ProAir Respiclick

Bronchospasm

ProAir Respiclick is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

ProAir Respiclick is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Proventil HFA

Proventil HFA Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Ventolin HFA

Bronchospasm

Ventolin HFA is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Ventolin HFA is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older.

Xopenex Solution

Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xopenex Concentrate

Xopenex (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xonenex HFA

Xopenex HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

REFERENCES

- 1. Albuterol sulfate 0.63mg and 1.25mg inhalation solution [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; May 2018.
- Albuterol 0.083% inhalation solution [package insert]. Parsippany, NJ: Actavis Pharma, Inc.; April 2017.
- 3. Albuterol 0.5% inhalation solution (0.5mL)[package insert]. Orlando, FL: Nephron Pharmaceuticals Corporation; February 2019.
- 4. Albuterol sulfate inhalation solution, 0.5% (20mL) [package insert]. Amityville, NY: HI-Tech Pharmacal Co., Inc.; February 2017.
- 5. ProAir Digihaler [package insert]. Frazer, PA: Teva Respiratory, LLC; October 2020.
- 6. ProAir HFA [package insert]. Frazer, PA: Teva Respiratory, LLC; August 2020.
- 7. ProAir Respiclick [package insert]. Horsham, PA: Teva Respiratory LLC; October 2020.
- 8. Proventil HFA [package insert]. Whitehouse Station, NJ: Merck&Co., Inc.; September 2017.
- 9. Ventolin HFA [package insert]. Research Triangle Park, NC: GlaxoSmithKline; September 2020.
- 10. Xopenex inhalation solution [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; December 2018.
- 11. Xopenex inhalation solution concentrate [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; December 2018.

Beta Agonists-Short Acting Oral Inhalation Limit Policy 1086-H 11-2020.docx

©2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

- 12. Xopenex HFA [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; February 2017.
- 13. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. http://online.lexi.com/. Accessed November 2020.
- 14. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http://www.micromedexsolutions.com/. Accessed November 2020.

<u>LIMIT CRITERIA</u> Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

| Medication* | Maintenance | Maximum | Package Size | 1 Month Limit* |
|---|--|-------------------------|-----------------------|--|
| | Dose | Daily Dose | | 3 Months Limit* |
| Albuterol | nebulization of | 4 vials | 25 vials (3mL each) | 5 packages (125 vials x 3mL) / 25 days |
| 0.63mg / 3mL, | 1 vial (3mL) | (3mL each) | per carton | 15 packages (375 vials x 3mL) / 75 days |
| 1.25mg / 3mL | three-four times daily | | 30 vials (3mL each) | 4 packages (120 vials x 3mL) / 25 days |
| (0.021%, 0.042%) | | | per carton | 12 packages (360 vials x 3mL) / 75 days |
| Inhalation Soln | | | | |
| Albuterol 0.083%, | nebulization of | 4 vials | 25 vials (3mL each) | 5 packages (125 vials x 3mL) / 25 days |
| 2.5mg / 3mL | 1 vial (3mL) three-four times daily | (3mL each) | per carton | 15 packages (375 vials x 3mL) / 75 days |
| Inhalation | lillee-lour tilles daily | | 30 vials (3mL each) | 4 packages (120 vials x 3mL) / 25 days |
| Solution | | | per carton | 12 packages (360 vials x 3mL) / 75 days |
| | | | 60 vials (3mL each) | 2 packages (120 vials x 3mL) / 25 days |
| | | | per carton | 6 packages (360 vials x 3mL) / 75 days |
| Albuterol 0.5%, | nebulization of | 2mL | 20mL | 3 packages (20mL each) / 25 days |
| 2.5mg / 0.5mL | 0.25mL-0.5mL three-four times daily | | per bottle | 9 packages (20mL each) / 75 days |
| Inhalation | tillee-lour tilles daily | | 30 vials (0.5mL each) | 4 packages (120 vials x 0.5mL) / 25 days |
| Solution | | | per carton | 12 packages (360vials x 0.5mL) / 75 days |
| ProAir Digihaler | 1-2 inhalations | 12 inhalations | 200 inhalations | 2 packages / 25 days |
| (albuterol) | every 4-6 hours | | per inhaler | 6 packages / 75 days |
| ProAir HFA | 1-2 inhalations | 12 inhalations | 200 inhalations | 2 packages (8.5gm each) / 25 days |
| (albuterol) | every 4-6 hours | 101111 | per 8.5gm canister | 6 packages (8.5gm each) / 75 days |
| ProAir RespiClick | 1-2 inhalations | 12 inhalations | 200 inhalations | 2 packages / 25 days |
| (albuterol) | every 4-6 hours | 10:11: | per inhaler | 6 packages / 75 days |
| Proventil HFA | 1-2 inhalations | 12 inhalations | 200 inhalations | 2 packages (6.7gm each) / 25 days |
| (albuterol) | every 4-6 hours | 10: 1 .1-4: | per 6.7gm canister | 6 packages (6.7gm each) / 75 days |
| Ventolin HFA | 1-2 inhalations every 4-6 hours | 12 inhalations | 60 inhalations | 6 packages (8gm each) / 25 days |
| (albuterol) | every 4-0 nours | | per 8gm canister | 18 packages (8gm each) / 75 days |
| | | | 200 inhalations | 2 packages (18gm each) / 25 days |
| <u> </u> | 1 2 2 - 1 | 2 | per 18gm canister | 6 packages (18gm each) / 75 days |
| Xopenex | nebulization of | 3 vials | 24 vials (3mL each) | 4 packages (96 vials x 3mL) / 25 days |
| 0.31mg,0.63mg, | 1 vial (3mL) three times daily | (3mL each) | per carton | 12 packages (288 vials x 3mL) / 75 days |
| 1.25 mg / 3 mL | tilloo tilloo daliy | | 25 vials (3mL each) | 4 packages (100 vials x 3mL) / 25 days |
| (levalbuterol) | | | per carton | 12 packages (300 vials x 3mL) / 75 days |
| i | | | 30 vials (3mL each) | 3 packages (90 vials x 3mL) / 25 days |
| | le di e e e e e | 0 : ::-1- | per carton | 9 packages (270 vials x 3mL) / 75 days |
| Xopenex | nebulization of 1 vial (0.5mL) | 3 vials (0.5mL each) | 30 vials (0.5mL each) | 3 packages (90 vials x 0.5mL) / 25 days |
| Concentrate | three times daily | (U.SITIL Eacity | per carton | 9 packages (270 vials x 0.5mL) / 75 days |
| 1.25mg / 0.5mL | tilloo tilloo daliy | | | |
| (levalbuterol) | 4.0 inhelations | 40 inhalations | 000 inhalations | 0 \ |
| Xopenex HFA | 1-2 inhalations every 4 to 6 hours | 12 inhalations | 200 inhalations | 2 packages (15gm each) / 25 days |
| (levalbuterol) | l | | per 15gm canister | 6 packages (15gm each) / 75 days |
| *The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing. | | | | |

Beta Agonists-Short Acting Oral Inhalation Limit Policy 1086-H 11-2020.docx

©2020 CVS Caremark. All rights reserved.